15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Corcept Therapeutics Incorporated, 4 rate it Buy or better, 0 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $50.00 to $165.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $122.60 sits 8% above the current $113.89. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.21 next quarter toward $4.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy480%
Hold00%
Sell120%
Strong Sell00%
Based on 5 analysts giving stock ratings to Corcept Therapeutics Incorporated.
As of Sep, 4 of 5 firms rate CORT a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
CORT EPS & revenue forecast
EPS · NEXT QUARTER
$1.21
Range $1.01 – $1.31 · 4 analysts · +503% YoY
Next period, 4 analysts expect Corcept Therapeutics Incorporated to earn $1.21 a share (range $1.01 – $1.31), versus $0.20 a year earlier. Full-year consensus is $2.15, growing to $4.40 the year after.
REVENUE · NEXT QUARTER
$388.7M
Range $378.2M – $403.0M · 4 analysts · +92% YoY
Revenue is expected to reach $388.7M (range $378.2M – $403.0M), +92.3% year-over-year. Full-year consensus is $1.1B, rising to $1.7B next year.
Top analysts covering Corcept Therapeutics Incorporated
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CORT.
#1
David Amsellem
Piper Sandler · Rank #107
Buy
$165.00+44.9% to target
Overall win rate
50%
+ Follow
#2
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #252
Buy
$165.00+44.9% to target
Overall win rate
38%
+ Follow
#3
EN
Edward Nash
Canaccord Genuity
Buy
$161.00+41.4% to target
Coverage
—
+ Follow
#4
KP
Kalpit Patel
Wolfe Research
Sell
$50.00-56.1% to target
Coverage
—
+ Follow
#5
Ashwani Verma
UBS
Buy
$72.00-36.8% to target
Coverage
—
+ Follow
CORT stock forecast FAQ
What is CORT's average 12-month price target?+
The 5 analysts with a live target average $122.60 for Corcept Therapeutics Incorporated over the next 12 months, ranging from a $165.00 high to a $50.00 low.
Is CORT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for CORT?+
The Street-high target is $165.00 (Piper Sandler), and the Street-low is $50.00 (Wolfe Research). The average of all 5 active targets is $122.60.
How many Wall Street analysts cover CORT?+
5 analysts have an active rating on Corcept Therapeutics Incorporated, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering CORT?+
Among analysts who currently cover CORT, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #107). Their current call is Buy with a $165.00 target.
What is Corcept Therapeutics Incorporated's projected EPS for next quarter?+
The consensus estimate is $1.21 per share (range $1.01 – $1.31) across 4 analysts. Full-year EPS is projected at $2.15, rising to $4.40 the following year.
How much revenue is Corcept Therapeutics Incorporated expected to report next quarter?+
Consensus revenue is $388.7M (range $378.2M – $403.0M). Full-year revenue is projected at $1.1B, growing to $1.7B next year.
Have analysts been upgrading or downgrading CORT lately?+
As of Sep, 4 of 5 firms rate CORT a Buy (0 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CORT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
